Recent ROIV News
- Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 • GlobeNewswire Inc. • 05/11/2026 08:05:00 PM
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 • GlobeNewswire Inc. • 05/11/2026 08:05:00 PM
- Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) • GlobeNewswire Inc. • 04/02/2026 09:00:00 AM
- Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) • GlobeNewswire Inc. • 04/02/2026 09:00:00 AM
- New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis • GlobeNewswire Inc. • 03/28/2026 07:00:00 PM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Roivant Secures FDA Priority Review for Dermatomyositis Treatment • IH Market News • 03/03/2026 04:09:50 PM
- Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis • GlobeNewswire Inc. • 03/03/2026 12:00:00 PM
- Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 • GlobeNewswire Inc. • 02/06/2026 12:00:00 PM
- Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) • GlobeNewswire Inc. • 02/06/2026 12:00:00 PM
- Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) • GlobeNewswire Inc. • 02/06/2026 12:00:00 PM
- Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 • GlobeNewswire Inc. • 01/23/2026 10:25:47 PM
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 • GlobeNewswire Inc. • 01/23/2026 09:15:00 PM
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day • GlobeNewswire Inc. • 12/11/2025 12:30:00 PM
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update • GlobeNewswire Inc. • 11/10/2025 12:00:00 PM
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 • GlobeNewswire Inc. • 10/27/2025 08:10:00 PM
- Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 • GlobeNewswire Inc. • 10/27/2025 08:10:00 PM
- Roivant Shares Jump on Positive Phase 3 Data for Dermatomyositis Therapy • IH Market News • 09/17/2025 02:28:54 PM
- Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) • GlobeNewswire Inc. • 09/17/2025 11:00:00 AM
- Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List • GlobeNewswire Inc. • 09/11/2025 08:30:00 PM
- Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) • GlobeNewswire Inc. • 09/04/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2025 05:38:54 PM
- Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients • GlobeNewswire Inc. • 09/03/2025 05:01:32 PM
